scholarly journals Long-Acting β2-Agonist Step-off in Patients With Controlled Asthma

2012 ◽  
Vol 172 (18) ◽  
pp. 1365 ◽  
Author(s):  
Jan L. Brozek ◽  
Monica Kraft ◽  
Jerry A. Krishnan ◽  
Michelle M. Cloutier ◽  
Stephen C. Lazarus ◽  
...  
Keyword(s):  
Long Acting ◽  
Β2 Agonist

scholarly journals Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study

BMJ Open ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. e049675
Author(s):  
Martine Hoogendoorn ◽  
Isaac Corro Ramos ◽  
Stéphane Soulard ◽  
Jennifer Cook ◽  
Erkki Soini ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
The Netherlands ◽  
Cost Effective ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Inhaled Corticosteroid ◽  
Dose Combination ◽  
Long Acting ◽  
Β2 Agonist ◽  
Country Specific

ObjectivesChronic obstructive pulmonary disease (COPD) guidelines advocate treatment with combinations of long-acting bronchodilators for patients with COPD who have persistent symptoms or continue to have exacerbations while using a single bronchodilator. This study assessed the cost-utility of the fixed dose combination of the bronchodilators tiotropium and olodaterol versus two comparators, tiotropium monotherapy and long-acting β2 agonist/inhaled corticosteroid (LABA/ICS) combinations, in three European countries: Finland, Sweden and the Netherlands.MethodsA previously published COPD patient-level discrete event simulation model was updated with most recent evidence to estimate lifetime quality-adjusted life years (QALYs) and costs for COPD patients receiving either tiotropium/olodaterol, tiotropium monotherapy or LABA/ICS. Treatment efficacy covered impact on trough forced expiratory volume in 1 s (FEV1), total and severe exacerbations and pneumonias. The unit costs of medication, maintenance treatment, exacerbations and pneumonias were obtained for each country. The country-specific analyses adhered to the Finnish, Swedish and Dutch pharmacoeconomic guidelines, respectively.ResultsTreatment with tiotropium/olodaterol gained QALYs ranging from 0.09 (Finland and Sweden) to 0.11 (the Netherlands) versus tiotropium and 0.23 (Finland and Sweden) to 0.28 (the Netherlands) versus LABA/ICS. The Finnish payer’s incremental cost-effectiveness ratio (ICER) of tiotropium/olodaterol was €11 000/QALY versus tiotropium and dominant versus LABA/ICS. The Swedish ICERs were €6200/QALY and dominant, respectively (societal perspective). The Dutch ICERs were €14 400 and €9200, respectively (societal perspective). The probability that tiotropium/olodaterol was cost-effective compared with tiotropium at the country-specific (unofficial) threshold values for the maximum willingness to pay for a QALY was 84% for Finland, 98% for Sweden and 99% for the Netherlands. Compared with LABA/ICS, this probability was 100% for all three countries.ConclusionsBased on the simulations, tiotropium/olodaterol is a cost-effective treatment option versus tiotropium or LABA/ICS in all three countries. In both Finland and Sweden, tiotropium/olodaterol is more effective and cost saving (ie, dominant) in comparison with LABA/ICS.

β2-Adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting β2-agonist therapy

1999 ◽  
Vol 96 (3) ◽  
pp. 253 ◽  
Author(s):  
B.J. LIPWORTH ◽  
I.P. HALL ◽  
I. AZIZ ◽  
K.S. TAN ◽  
A. WHEATLEY
Keyword(s):  
Agonist Therapy ◽  
Long Acting ◽  
Β2 Agonist

scholarly journals Long acting β2-agonist and corticosteroid restore airway glandular cell function altered by bacterial supernatant

2010 ◽  
Vol 11 (1) ◽  
Author(s):  
Jean-Marie Zahm ◽  
Franck Delavoie ◽  
Férial Toumi ◽  
Béatrice Nawrocki-Raby ◽  
Claire Kileztky ◽  
...  
Keyword(s):  
Cell Function ◽  
Glandular Cell ◽  
Long Acting ◽  
Β2 Agonist

Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting β2-agonist, in patients with mild asthma

2009 ◽  
Vol 124 (6) ◽  
pp. 1217-1221 ◽  
Author(s):  
Paul M. O'Byrne ◽  
Just van der Linde ◽  
Donald W. Cockcroft ◽  
Gail M. Gauvreau ◽  
John D. Brannan ◽  
...  
Keyword(s):  
Mild Asthma ◽  
Long Acting ◽  
Β2 Agonist
Sign in / Sign up

Export Citation Format

Share Document